$CRBU News
Last published 1w ago
- 1w agoCRBUCaribou Biosciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCRBUCaribou Biosciences Reports Third Quarter 2026 Financial ResultsGlobeNewswireBERKELEY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU) today reported financial results for the third quarter of 2026. Third quarter 2026 financial resultsLicensing and other
- 1w agoCRBUCaribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual MeetingGlobeNewswireBERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster
- 1mo agoCRBUCaribou Biosciences to Evaluate Strategic AlternativesGlobeNewswire-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents, and marketable
- 3mo agoCRBUCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers
- 4mo agoCRBUCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswireBERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s
- 5mo agoCMPXCRBUFATEGTBP+1After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellGlobeNewswireIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
- 5mo agoCRBUCaribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026GlobeNewswire-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient administration and
- 5mo agoCRBUCaribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual MeetingGlobeNewswire-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case study of a patient
- 5mo agoCRBUJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - CARIBOU BIOSCIENCES INCEarnings Call TranscriptsWelcome. Rachel Horwitz, the CEO of Caribou Biosciences. Thanks so much for joining us today, Rachel. Thanks for having us. And for those who are new to the story, maybe give a one-minute intro to the company. Absolutely
- 5mo agoCRBUCaribou Biosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 6mo agoCRBUCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor ConferenceGlobeNewswireBERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's management team will
- 6mo agoCRBU2026 Global Healthcare Conference - CARIBOU BIOSCIENCES INCEarnings Call TranscriptsAll right, let's get going. Thanks for joining this session with Caribou Biosciences. My name is Alex Dranahan. I cover SMID biotech at Bank of America, and I'm pleased to welcome Rachel Horwitz, president and CEO of Car
- 6mo agoCRBUCaribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual MeetingGlobeNewswireBERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for
- 6mo agoCRBUCaribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMouflage phase 1 trial
- 6mo agoCRBUCaribou Biosciences to Participate in the BofA Securities 2026 Health Care ConferenceGlobeNewswireBERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 7mo agoCRBUCaribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell TherapyGlobeNewswire-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient
- 8mo agoCRBUCaribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireBERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth
- 9mo agoCRBUCaribou Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the
- 9mo agoCRBUCaribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®GlobeNewswireClinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data demonstrate efficacy
- 10mo agoCRBUGTBPLYELNRIX+1Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market SurgeGlobeNewswireVANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a
- 11mo agoCRBUCaribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025GlobeNewswireKOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting BERKELEY, Calif.,
- 1y agoCRBUCaribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireVispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class allogeneic CAR-T
- 1y agoCRBUCaribou Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the
- 1y agoCRBUCaribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell TherapiesGlobeNewswireData demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on
- 1y agoCRBUCaribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple MyelomaGlobeNewswireFirst clinical data disclosure for CB-011 highlights its potential as a best-in-class allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma450 million cell dose is the recommended dose for expansion
- 1y agoCRBUCaribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple MyelomaGlobeNewswireBERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast
- 1y agoCRBUCaribou Biosciences to Participate in the Citi 2025 Biopharma Back to School ConferenceGlobeNewswireBERKELEY, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 1y agoCRBUCaribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan
- 1y agoCRBUCaribou Biosciences to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireBERKELEY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 1y agoCRBUCaribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company's current operating plan
- 1y agoCRBUCaribou Biosciences to Participate in the BofA Securities 2025 Health Care ConferenceGlobeNewswireBERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 1y agoCRBUCaribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology ProgramsGlobeNewswire-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now expected to be
- 1y agoCRBUCaribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases -- -- $249.4 million in cash,
- 1y agoCRBUShareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBUPR NewswireThe Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU ...
- 1y agoCRBUThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBUGlobeNewswireNEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ:CRBU). Shareholders who purchased shares of CRBU during the class
- 1y agoCRBUSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou BiosciencesGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Caribou To Contact Him Directly To Discuss Their Options If you suffered losses
- 1y agoCRBUCaribou Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 1y agoCRBUCaribou Biosciences, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBUPR NewswireThe Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU ...
- 1y agoCRBUDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou BiosciencesGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in
- 1y agoCRBUCaribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CRBUPR NewswireThe Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU ...
- 1y agoCRBUShareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your Rights - CRBUPR NewswireThe Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). Shareholders who purchased shares of CRBU ...
- 1y agoCRBUCaribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025GlobeNewswire-- CB-010 GALLOP Phase 1 trial initiated in lupus -- -- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 -- -- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage
- 1y agoCRBUCaribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBERKELEY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Rachel Haurwitz, PhD,
- 1y agoCRBUThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBUGlobeNewswireNEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ:CRBU). Shareholders who purchased shares of CRBU during the class period
- 1y agoCRBUCaribou Biosciences Appoints Sri Ryali as Chief Financial OfficerGlobeNewswireBERKELEY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sri Ryali as
- 1y agoCRBUCaribou Biosciences to Participate in Upcoming Investor ConferencesGlobeNewswireBERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's
- 2y agoCRBUCaribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior CD19-targeted
- 2y agoCRBUCaribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024GlobeNewswireBERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for
- 2y agoCRBUCaribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AMLGlobeNewswire-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track designations in B-NHL -- --